Key Stats for Hims & Hers Stock
- Price change for Hims & Hers stock Today: 37%
- $HIMS Share Price as of Mar. 6: $16
- 52-Week High: $70
- $HIMS Stock Price Target: $22
Now Live: Discover how much upside your favorite stocks could have using TIKR’s new Valuation Model (It’s free)>>>
What Happened?
Hims & Hers stock (HIMS) surged nearly 50% after Novo Nordisk dropped its patent lawsuit against the telehealth company and struck a partnership deal instead.
Under the new agreement, Hims will sell Novo’s branded weight loss medications, including Ozempic and Wegovy (both forms of semaglutide), at the same prices offered by other telehealth platforms.
In return, Hims agreed to stop advertising compounded GLP-1 drugs on its platform and reserve compounding only for rare cases where customization is medically necessary.
“We have decided to drop the current court proceedings,” Novo Nordisk CEO Mike Doustdar told CNBC. “Hims & Hers have agreed that upon receiving our products, they will no longer advertise, promote, market compounded products to the masses.”
The lawsuit stemmed from Hims’ February announcement that it would sell a copycat Wegovy pill for $49, roughly $100 cheaper than Novo’s branded version.
Hims quickly pulled the pill after facing backlash from both Novo and the FDA, which promised to crack down on compounding pharmacies exploiting regulatory loopholes.
Hims had profited significantly by selling compounded versions of semaglutide, claiming the drugs were “personalized” and therefore legal despite semaglutide’s patent protection lasting until 2032.
See analysts’ growth forecasts and price targets for Hims & Hers stock (It’s free!) >>>
What the Market Is Telling Us About Hims & Hers Stock
The dramatic rally in Hims & Hers stock signals strong investor confidence that this partnership resolves major regulatory and legal risks while opening new revenue opportunities.
By gaining access to Novo’s branded medications, Hims can continue serving the booming weight loss market without legal uncertainty.
Hims CEO Andrew Dudum noted the rapidly evolving landscape for anti-obesity drugs.
“The demand will continue to accelerate with the new assortment that’s coming out,” he told CNBC, adding that Hims is in conversations with biotech firms and large drug companies to bring additional therapies to its platform.
With over 2.5 million subscribers and strong momentum in international expansion following recent acquisitions, Hims & Hers stock appears positioned for continued growth as the company transitions from compounded drugs to branded partnerships.
Estimate a company’s fair value instantly (Free with TIKR) >>>
How Much Upside Does Hims & Hers Stock Have From Here?
With TIKR’s new Valuation Model tool, you can estimate a stock’s potential share price in under a minute.
All it takes is three simple inputs:
- Revenue Growth
- Operating Margins
- Exit P/E Multiple
If you’re not sure what to enter, TIKR automatically fills in each input using analysts’ consensus estimates, giving you a quick, reliable starting point.
From there, TIKR calculates the potential share price and total returns under Bull, Base, and Bear scenarios so you can quickly see whether a stock looks undervalued or overvalued.
See a stock’s true value in under 60 seconds (Free with TIKR) >>>
Looking for New Opportunities?
- See what stocks billionaire investors are buying so you can follow the smart money.
- Analyze stocks in as little as 5 minutes with TIKR’s all-in-one, easy-to-use platform.
- The more rocks you overturn… the more opportunities you’ll uncover. Search 100K+ global stocks, global top investor holdings, and more with TIKR.
Disclaimer:
Please note that the articles on TIKR are not intended to serve as investment or financial advice from TIKR or our content team, nor are they recommendations to buy or sell any stocks. We create our content based on TIKR Terminal’s investment data and analysts’ estimates. Our analysis might not include recent company news or important updates. TIKR has no position in any stocks mentioned. Thank you for reading, and happy investing!
